IRADIMED CORPORATION
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $22.5M | $19.2M | $17.2M | $12.8M | $9.3M | $1.4M | $9.6M | $6.3M |
| Depreciation & Amortization | $1.2M | $818.0K | $765.2K | $670.7K | $1.4M | $1.3M | $1.2M | $1.1M |
| Depreciation | $796.0K | $586.0K | $648.1K | $569.6K | $532.3K | $510.7K | $501.2K | $470.4K |
| Amortization | $370.0K | $232.0K | $117.0K | $101.1K | $101.7K | $92.9K | $90.0K | $89.3K |
| Stock-Based Compensation | $2.9M | $2.5M | $2.2M | $1.4M | $1.5M | $4.0M | $1.9M | $1.8M |
| Net Cash from Operating Activities | $24.9M | $25.6M | $13.5M | $10.0M | $11.3M | $5.8M | $10.2M | $7.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $7.8M | $8.0M | $7.4M | $823.0K | $482.3K | $443.0K | $368.3K | $228.3K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-8.4M | $-8.8M | $-8.0M | $-1.4M | $648.2K | $247.0K | $3.2M | $1.5M |
| Financing Activities | ||||||||
| Dividends Paid | $15.0M | $13.7M | $13.2M | $12.6M | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-17.6M | $-14.3M | $-13.7M | $-12.7M | $24.4K | $522.5K | $2.0M | $929.9K |
| Net Change in Cash | $-1.1M | $2.5M | $-8.2M | $-4.0M | $11.9M | $6.6M | $15.5M | $9.8M |
| Free Cash Flow | $17.2M | $17.6M | $6.0M | $9.2M | $10.8M | $5.4M | $9.9M | $7.1M |